UNLABELLED: Pain medication has been associated with fractures. We found higher weight in paracetamol and non-steroidal anti-inflammatory drugs (NSAID) users and lower vitamin D levels in opioid and acetylsalicylic acid users. None of the pain medications influenced bone mineral density or loss. NSAID were associated with an increased fracture risk. INTRODUCTION: To study the effects of use of paracetamol, non-steroidal anti-inflammatory drugs (NSAID), acetylsalicylic acid (ASA), and opioids on bone mineral density (BMD) and risk of fractures. METHODS: Two-thousand sixteen perimenopausal women followed for 10 years as part of a partly randomised comprehensive cohort study on hormone therapy (HT). BMD was measured at baseline and after 10 years by DXA (Hologic). RESULTS: Paracetamol users were heavier (70.4 ± 13.4 vs. 67.7 ± 11.9 kg, 2p < 0.01) than non-users. NSAID users were heavier (71.6 ± 15.6 vs. 67.8 ± 11.9 kg, 2p = 0.04) than non-users. ASA users had lower 25-hydroxy-vitamin D (25OHD) levels (21.9 ± 9.3 vs. 25.3 ± 12.4 ng/ml, 2p < 0.01) than non-users. Opioid users had lower 25OHD (21.4 ± 8.4 vs. 25.2 ± 12.3 ng/ml) and lower intake of vitamin D (2.2 ± 1.1 vs. 3.1 ± 3.0 μg/day, 2p < 0.01) than non-users. Despite these differences, no baseline differences were present in spine, hip, forearm or whole body BMD. Over 10 years, no differences were present in BMD alterations except a small trend towards a higher BMD gain in the spine in users of paracetamol, NSAID, ASA, and opioids compared to non-exposed. After adjustment, NSAID exposed sustained more fractures (HR = 1.44, 95% CI 1.07-1.93) than non-users. For users of paracetamol and opioids, a non-significant trend towards more fractures was present after adjustment. For ASA users, no excess risk of fractures was present. CONCLUSION: Significant differences exist between subjects exposed to pain medications and non-users. Despite an absence of an effect over time on BMD, users of NSAID experienced more fractures than expected. The reasons for this have to be explored in further studies.
UNLABELLED: Pain medication has been associated with fractures. We found higher weight in paracetamol and non-steroidal anti-inflammatory drugs (NSAID) users and lower vitamin D levels in opioid and acetylsalicylic acid users. None of the pain medications influenced bone mineral density or loss. NSAID were associated with an increased fracture risk. INTRODUCTION: To study the effects of use of paracetamol, non-steroidal anti-inflammatory drugs (NSAID), acetylsalicylic acid (ASA), and opioids on bone mineral density (BMD) and risk of fractures. METHODS: Two-thousand sixteen perimenopausal women followed for 10 years as part of a partly randomised comprehensive cohort study on hormone therapy (HT). BMD was measured at baseline and after 10 years by DXA (Hologic). RESULTS:Paracetamol users were heavier (70.4 ± 13.4 vs. 67.7 ± 11.9 kg, 2p < 0.01) than non-users. NSAID users were heavier (71.6 ± 15.6 vs. 67.8 ± 11.9 kg, 2p = 0.04) than non-users. ASA users had lower 25-hydroxy-vitamin D (25OHD) levels (21.9 ± 9.3 vs. 25.3 ± 12.4 ng/ml, 2p < 0.01) than non-users. Opioid users had lower 25OHD (21.4 ± 8.4 vs. 25.2 ± 12.3 ng/ml) and lower intake of vitamin D (2.2 ± 1.1 vs. 3.1 ± 3.0 μg/day, 2p < 0.01) than non-users. Despite these differences, no baseline differences were present in spine, hip, forearm or whole body BMD. Over 10 years, no differences were present in BMD alterations except a small trend towards a higher BMD gain in the spine in users of paracetamol, NSAID, ASA, and opioids compared to non-exposed. After adjustment, NSAID exposed sustained more fractures (HR = 1.44, 95% CI 1.07-1.93) than non-users. For users of paracetamol and opioids, a non-significant trend towards more fractures was present after adjustment. For ASA users, no excess risk of fractures was present. CONCLUSION: Significant differences exist between subjects exposed to pain medications and non-users. Despite an absence of an effect over time on BMD, users of NSAID experienced more fractures than expected. The reasons for this have to be explored in further studies.
Authors: C De Laet; J A Kanis; A Odén; H Johanson; O Johnell; P Delmas; J A Eisman; H Kroger; S Fujiwara; P Garnero; E V McCloskey; D Mellstrom; L J Melton; P J Meunier; H A P Pols; J Reeve; A Silman; A Tenenhouse Journal: Osteoporos Int Date: 2005-06-01 Impact factor: 4.507
Authors: L Mosekilde; H Beck-Nielsen; O H Sørensen; S P Nielsen; P Charles; P Vestergaard; A P Hermann; J Gram; T B Hansen; B Abrahamsen; E N Ebbesen; L Stilgren; L B Jensen; C Brot; B Hansen; C L Tofteng; P Eiken; N Kolthoff Journal: Maturitas Date: 2000-10-31 Impact factor: 4.342
Authors: S Silberstein; S Tepper; J Brandes; M Diamond; J Goldstein; P Winner; S Venkatraman; F Vrijens; W Malbecq; C Lines; W H Visser; S Reines; E Yuen Journal: Neurology Date: 2004-05-11 Impact factor: 9.910
Authors: Laura D Carbone; Frances A Tylavsky; Jane A Cauley; Tamara B Harris; Thomas F Lang; Douglas C Bauer; Karen D Barrow; Stephen B Kritchevsky Journal: J Bone Miner Res Date: 2003-10 Impact factor: 6.741
Authors: H A Bischoff; H B Stahelin; N Urscheler; R Ehrsam; R Vonthein; P Perrig-Chiello; A Tyndall; R Theiler Journal: Arch Phys Med Rehabil Date: 1999-01 Impact factor: 3.966
Authors: Anna L Barker; John J McNeil; Ego Seeman; Stephanie A Ward; Kerrie M Sanders; Sundeep Khosla; Robert G Cumming; Julie A Pasco; Megan A Bohensky; Peter R Ebeling; Robyn L Woods; Jessica E Lockery; Rory Wolfe; Jason Talevski Journal: Inj Prev Date: 2015-05-21 Impact factor: 2.399
Authors: Laura D Carbone; Amy S Chin; Todd A Lee; Stephen P Burns; Jelena N Svircev; Helen M Hoenig; Titilola Akhigbe; Frances M Weaver Journal: J Spinal Cord Med Date: 2013-03 Impact factor: 1.985
Authors: Kazuki Yoshida; Zhi Yu; Gail A Greendale; Kristine Ruppert; Yinjuan Lian; Sara K Tedeschi; Tzu-Chieh Lin; Sebastien Haneuse; Robert J Glynn; Sonia Hernández-Díaz; Daniel H Solomon Journal: Pharmacoepidemiol Drug Saf Date: 2017-12-12 Impact factor: 2.890
Authors: Anne Claire B van Orten-Luiten; André Janse; Rosalie A M Dhonukshe-Rutten; Renger F Witkamp Journal: Drugs Aging Date: 2014-02 Impact factor: 3.923
Authors: Chandan Vangala; Jingbo Niu; Maria E Montez-Rath; Jingyin Yan; Sankar D Navaneethan; Aanand D Naik; Wolfgang C Winkelmayer Journal: J Am Soc Nephrol Date: 2020-05-05 Impact factor: 10.121